Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Liver Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost

James Pingpank, MD

To evaluate the safety, toxicity and immunological effects of adjuvant administration of an experimental therapy consisting on priming with three intramuscular administrations of a plasmid expressing human AFP (phAFP) together with a plasmid expressing human GM-CSF (phGM-CSF), followed by a single intramuscular boost with an AFP adenoviral vector (AdVhAFP) to patients with locoregionally pre-treated hepatocellular carcinoma (HCC).

Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma

A Phase I/II Trial Testing Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma

National Cancer Institute (NCI)

Lisa H. Butterfield, Ph.D.

Professor of Medicine, Surgery and Immunology

Symptoms and General Pathology

Neoplasm Metastasis

Colorectal Neoplasms

Intestinal Neoplasms

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Neoplastic Processes

Central Nervous System Depressants

All Drugs and Chemicals

Hematinics

Coagulants

Anti-Infective Agents

Anesthetics

Liver Extracts

Hemostatics

Formaldehyde

Patients will be given general anesthesia. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. Once the operating surgeon determines that the lesions as evaluated on intraoperative ultrasound remain amenable to MWA, ablations will be performed with a 2.45-gigahertz (GHz) generator with a 1.8-mm-diameter transcutaneous antenna (Acculis pMTA Accu2i; AngioDynamics Inc., Denmead, Hampshire, UK). Additional ablations will be performed sequentially. Laparoscopic core needle biopsy of lesions will be performed and submitted for permanent pathologic sectioning per current treatment standards. At the conclusion of the ablation, a collapsed titanium clip will be inserted into the microwave antenna tract as a radiographic fiducial marker. Hemostasis of the ablation track will be ensured using a combination of microwave energy, monopolar electrocautery, and/or topical hemostatics.

General anesthesia will be induced. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. The liver will be evaluated with intraoperative ultrasound (BK Medical A/S, Herlev, Denmark). Laparoscopic core needle biopsy of lesions will be performed. Partial hepatectomy may be carried out with parenchymal precoagulation with radiofrequency electrosurgical devices such as the LigaSure™ (Covidien, Medtronic; Minneapolis, MN), Harmonic® (Ethicon Endosurgery; Cincinnati, OH), or saline-coupled radiofrequency ablation device (Aquamantys™; Covidien/Medtronic; Minneapolis, MN); hepatic parenchymal transection can be performed as above or with the use of stapling devices to ligate and divide parenchyma. Hepatic vascular inflow occlusion will be performed at the surgeon's discretion. A topical hemostatic may be used along the transected hepatic parenchyma. Resected specimens will be preserved in formalin for pathology.

Laparoscopic or robot-assisted laparoscopic microwave ablation of cancerous lesions with a 2.45-GHz microwave generator and a 1.8-mm-diameter transcutaneous antenna.

Microwave ablation

Laparoscopic or robot-assisted laparoscopic surgical resection of cancerous lesions.

Hepatic resection

Dionisios Vrochides, MD PhD

This single-center, prospective, randomized clinical trial is designed to compare the clinical characteristics and outcomes of hepatic resection and microwave ablation (MWA) to determine the optimal operative intervention for the local treatment of resectable colorectal cancer liver metastases. The primary aim of this study is to test the following hypothesis: 2-year local disease control is equivalent between patients receiving the experimental therapy (MWA) and patients receiving the standard therapy (hepatic resection) as treatment for colorectal cancer liver metastases determined to be resectable by radiographic imaging. Secondarily, the investigators expect that 2-year intrahepatic (regional) and metastatic disease recurrence rates are equivalent between the two treatment arms in this study.

Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases

Prospective Randomized Comparison of Resection and Microwave Ablation for Resectable Colorectal Cancer Liver Metastases

Local disease control is measured from time of randomization and is defined as the absence of local recurrence of metastatic adenocarcinoma of the colon or rectum as determined by diagnostic imaging.

Wake Forest University Health Sciences

Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips.

Liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (\<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips.

Hui Chuan Sun, Professor

Jia Fan, Professor

Jian Zhou, Professor

Shuang Jian Qiu, Professor

Guo Ming Shi, Asso. Prof.

Qing Hai Ye, Professor

Lu Wang, Professor

Xiao Wu Huang, Professor

Ning Ren, Professor

Jing Xian Yu, Nurse

Yang Xu, Asso. Prof.

Ying Hong Shi, Asso. Prof.

Xiao Ying Wang, Asso. Prof

Jian Sun, Asso. Prof.

Zheng Wang, Asso. Prof.

Yong Sheng Xiao, Asso. Prof.

Pei Chen, Asso. Prof.

Cheng Huang, Asso. Prof.

Ying Hao Shen, Asso. Prof.

Blood loss during liver resection significantly associates with short term operative outcome. The median blood loss during partial liver resection is 700-1200ml in high-volume centers. Conventional method (crush-clamp) has been a standard technique for liver transection. Technique advances related to liver transection have contributed to reduction in blood loss. Several studies have showed that Harmonic Scalpel in liver resection is safe and easy to use. A nonrandomized study showed use of the Harmonic Scalpel was associated with decreased operative time, blood loss and transfusion requirement, and an increased incidence of postoperative bile leakage. However, no randomized study has compared the difference between liver resection using traditional technology and harmonic Scalpel. The objective of this prospective randomized study is to compare the safety and efficacy of liver resection using the harmonic scalpel device with the "crush-clamp" technique in respect to blood loss, liver transection time, hepatic hilum clamping time, hospital stay and postoperative complications.

Blood loss during liver resection significantly associates with short term operative outcome. The median blood loss during partial liver resection is 700-1200ml in high-volume centers. Conventional method (crush-clamp) has been a standard technique for liver transection. Technique advances related to liver transection have contributed to reduction in blood loss. Several studies have showed that Harmonic Scalpel in liver resection is safe and easy to use. A nonrandomized study showed use of the Harmonic Scalpel was associated with decreased operative time, blood loss and transfusion requirement, and an increased incidence of postoperative bile leakage. However, no randomized study has compared the difference between liver resection using traditional technology and harmonic Scalpel. The objective of this prospective randomized study is to compare the safety and efficacy of liver resection using the harmonic scalpel device with the "crush-clamp" technique in respect to blood loss, liver transection time, hepatic hilum clamping time, hospital stay and postoperative complications. All patients submitted to liver resection are randomized into two groups: those submitted to liver resection with the use of "crush-clamp" technique. (group Α) and those with the use of the Harmonic Scalpel device (group Β).

Crush-clamping Method (group A) :Patients submitted to liver resection with the use of "crush-clamping" technique.

Device: Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips.

Harmonic Scalpel (group B) :Patients submitted to liver resection with the use of the Harmonic Scalpel device.Device: liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (\<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips.

Primary Outcome Measures:

Blood loss during operation \[an expected average of 3 hours\] operation\]\[Designated as safety issue: Yes\] Postoperative complications including bile leakage, bleeding, morbidity, injured Liver function \[Time Frame: participants will be followed for the duration of hospital stay, an expected average of 8 days\] \[Designated as safety issue: Yes\]

Secondary Outcome Measures:

Transection time from Mark of the cutting edge to finish disposed of the cutting edge \[Designated as safety issue: No\] Hepatic hilar clamping time (Pringle's method) \[the duration of clamping of hepatic hilar\] \[Designated as safety issue: No\] Hospital stay \[participants will be followed for the duration of hospital stay, an expected average of 8 days\] \[Designated as safety issue: No\] Enrollment: 128 Study Start Date: June 2014 Study Completion Date: May 2015 Primary Completion Date: May 2015 (Final data collection date for primary outcome measure)

Eligibility:

Genders Eligible for Study: Both Accepts Healthy Volunteers: No

Criteria:

Inclusion Criteria:

1. Age ≥18y, and ≤80y;
2. No history of liver resection and radiotherapy
3. Liver function: Child A with a normal prothrombin time (\<13 seconds) and international normalized ratio (INR )(\<1.15);
4. Extent of resection ≥2 segment or diameter of tumor (single nodule) ≥ 8cm or cumulative diameter of tumor (multiple nodule) ≥ 8cm; Eligible patients will be stratified by resection in left lobe or right lobe.
5. No tumor thrombosis in main trunk or right and left branch of portal vein or major hepatic vein.

Exclusion Criteria:

1. Recurrent liver tumor; or simultaneous resection of other organs except gallbladder
2. Prothrombin time \> 13seconds;
3. Blood platelets count (BPC) \< 60\*109
4. Moderate and severe of esophageal varices detected by CT or MRI
5. Diameter of portal vein \> 14mm (color ultrasound)

Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method

Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method: A Prospective Randomized Study

Amount of blood loss will be assayed during operation.

Liver transection time from Mark of the cutting edge to finish disposed of the cutting edge will be recorded.

Hepatic hilar clamping time (Pringle's method) will be recorded.

Postoperative complications including bile leakage, bleeding, morbidity, injured Liver function will be recorded.

Hui-Chuan Sun

Professor

Antineoplastic Agents

Sorafenib

Patients with advanced HCC who have experienced tumor progression with sorafenib will receive ABC294640.

ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously.

ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days.

ABC294640

Micheal Lilly, MD

This is a Phase II study of single agent ABC294640. Patients with advanced hepatocellular carcinoma (HCC) who have experienced tumor progression or unacceptable toxicity on single agent sorafenib will receive ABC294640 500 mg by mouth twice a day continuously. Patients will continue on study drug until the development of progressive disease per modified RECIST, intolerable toxicity, withdrawal of patient consent or other event as outlined in patient discontinuation.

A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma

A Phase II Study of ABC294640 in Patients With Advanced Hepatocellular Carcinoma Who Have Progressed on Sorafenib

Radiographic Assessment will be completed up to 28 days prior to registration and every 8 weeks (+/- 7 days) following registration until disease progression or other (e.g.toxicity, patient decision, etc). The baseline radiographic assessment will include CT or MRI of the chest, abdomen and pelvis. Subsequent imaging will include only those body regions that include measureable index lesions per modified RECIST. Radiographic assessments will be completed every 8 weeks (+/- 7 days). In regards to the end of treatment visit, if the patient is taken off study and already has radiographic documentation of progressive disease, completing the radiographic assessment at the end of treatment visit is not required per study. If the patient is taken off study for other reasons such as toxicity or patient decision, it is strongly recommended that a radiographic assessment be obtained.

Patients who have not progressed by the end of the follow-up will have their TTP values censored.

Survival times will be censored for patients lost to follow-up or still alive at the trial's termination.

Blood samples will be drawn. Plasma or PK analysis for ABC294640 will be collected on:

* Cycle 1 (each cycle is 28 days) Day 1 prior to and at 2 and 8 hours post ABC294640 dosing
* Prior to dosing on and at 2 hours post dose Cycle 1 Day 15
* Prior to dosing on Cycle 2 Day 1.

Scatterplots of percent change in target lesions versus change in marker levels will be constructed. Variable transformations will be considered as needed and Pearson or Spearman correlation coefficients will be constructed as appropriate. The sample size of 39 provides a minimum of 80% power to detect a correlation of at least ± 0.44 versus a null correlation of 0.

All AEs and SAEs whether volunteered by the subject, discovered by study personnel during questioning, or detected through physical examination, laboratory test, or other means will be reported appropriately. Each reported AE or SAE will be described by its duration (i.e., start and end dates), regulatory seriousness criteria if applicable, suspected relationship to the study, and actions taken. Adverse events will be coded by body system and summary of table with incidence rates of AEs will be generated. Severity, duration, investigator attributed relationship to study drug and adverse event outcomes will be reported.

Scatterplots of percent change in target lesions versus change in immune cell subsets will be constructed. Variable transformations will be considered as needed and Pearson or Spearman correlation coefficients will be constructed as appropriated. The sample size of 39 provides a minimum of 80% power to detect a correlation of at least ± 0.44 versus a null correlation of 0.

Apogee Biotechnology Corporation

Medical University of South Carolina

Resovist (BAY86-4884, SH U 555 A)

Bayer Study Director

Patients with suspicion of primary or secondary hepatic malignancy in whom a radiological examination is needed in order to decide on the most appropriate treatment.

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.

Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Identification of Hepatic Lesions

A Prospective, Multicenter, Phase III b Clinical Study to Evaluate the Effectiveness of Unenhanced and SH U 555A (Resovist) Enhanced MRI, Compared to Contrast-Enhanced Dual-Phase Spiral CT in Assessing the Correct Final Therapy-Deciding Diagnosis, in Patients With Primary or Secondary Hepatic Malignancies.

Bayer

Therapeutic Area Head

Body Weight

Anticonvulsants

Psychotropic Drugs

Nitrazepam

Patients who are enrolled in the study will undergo an additional diffusion weighted MRI (T2W, DWI and ADC sequences) of the liver.

Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local site policy.

Diffusion Weighted MRI scan

Caroline Martin

Syvella Ellis

Pippa Hill

Lesley Wilkinson

Chris Smart

Helena Cox

Manjusha Keni

Lauren Shillito

Peng Lee

Raksha Mistry

Gemma Faulkner

Suzie Rayner

Iheoma Amaechi

Lindsay Piper

Sarah Duff

Matthew Noonan

Catriona Farrell

Julie Storer

Michelle Swann

Ravivarma Balasubramaniam

Cordelia Grant

Christos Kontovounisios

Heeam Nassa

Mark Robinson

Pritpal Klear

Holly Lawrence

Jamal Abdulkarim

Ruth Casey

Graham Branagan

Nicola Gibbons

Antony Higginson

Gina Brown

Eligible patients with high risk colorectal malignancy (T3/4, spread greater than 5mm, EMVI positive) will have additional surveillance of breath hold T1, T2 and DW-MRIs (no IV contrast) post surgery six monthly for three years.

Findings of liver MRIs as reported by radiology PI will be shared with their local MDT who make decisions as appropriate, including the management of any identified liver metastases, according to local protocol.

A phase II multicentre, interventional study to determine if additional staging at diagnosis with liver DW-MRI will diagnose more synchronous metastases than CT alone in patients with high risk colorectal cancer. Liver metastases found on the additional DW-MRI scans will be discussed at MDT and treated according to local policy.

Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)

Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI.

Proportion of additional patients diagnosed with liver metastases on DW MRI compared with CT.

% of patients diagnosed with liver metastases according to known prognostic risk factors

% lesions suspected as metastatic on DW MRI confirmed by subsequent 'gold standard' of contrast enhanced MRI and/or surgical resection, and/or progressive enlargement of the lesion.

Survival and recurrence outcomes according to presence or absence of liver metastases

Fong score of all patients with liver metastases

Proportion of patients undergoing curative treatment and methods of treatment

Pelican Cancer Foundation

Imperial College London

Rectal Neoplasms

Colonic Neoplasms

Herbal and Botanical

Cola

Stage 1: Four escalating dose cohorts of NV1020 3x10\^6 pfu, 1x10\^7 pfu, 3x10\^7 pfu, and 1x10\^8 pfu administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy.

Stage 2: Expansion of one dose cohort from Stage 1 of optimal NV1020 dose administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks followed by 2 cycles of chemotherapy.

NV1020 dose levels: 3x10\^6, 1x10\^7, 3x10\^7, and 1x10\^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks

NV1020

Hoda Tawfik, PhD

This study is an open-label study. It has two stages. Stage 1 is a dose escalation phase of the study to determine and evaluate the safety and tolerability of repeated treatments with a genetically engineered herpes simplex virus NV1020 administered locoregionally to the liver.

Stage 2 is to evaluate the dose found in Stage 1 to be "optimally tolerated". Stage 2 is to assess the efficacy of the optimally tolerated dose of NV1020 by itself and in combination with second-line chemotherapy.

Assignment to Stage 1 or Stage 2 of the study is determined by when the patient enters the study.

This study is designed to evaluate the effects of repeated treatments with NV1020, prior to second-line chemotherapy, and to determine an appropriate dose level of NV1020 in a multiple dose regimen for later Phase II studies.

Sequential, open-label cohort dose escalation of NV1020 (stage 1) followed by an expansion of one selected dose cohort (stage 2).

Study results will be reviewed periodically by an independent DSMB who will approve each cohort dose escalation.

During the dose escalation stage, 3 cohorts of patients (3 in each) will be treated with 4 fixed doses of NV1020, with the dose level increasing for successive cohorts. A patient will be observed for a minimum of 7 days after the first NV1020 infusion before the next patient in the same cohort is given NV1020. The first patient in the next higher dose cohort will receive NV1020 no earlier than 14 days after the last patient in the prior cohort has finished NV1020 infusions. One additional cohort (half log higher increment) may be approved by the DSMB, if considered necessary to define MTD. Dose-limiting toxicity will be determined using NCI CTC criteria and a suitable dose level for later evaluation will be selected.

In the second stage of the study, the dose cohort considered to show the best therapeutic index will be expanded by the addition of 18 further patients. For all patients in this study, investigational treatment with NV1020 will be followed by a minimum of two cycles of second-line therapy using anti-neoplastic drugs approved by the FDA for colorectal cancer and selected by the investigator.

All patients will be followed up periodically until death. Permission for autopsy will be sought.

Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver

A Phase I/II, Open-label Study to Evaluate the Safety and Anti-tumor Effects of NV1020 Administered Repeatedly Via Hepatic Artery Infusion Prior to Second-line Chemotherapy, in Patients With Colorectal Adenocarcinoma Metastatic to the Liver

Incidence of adverse events for all patients (N=32); Overall incidence ≥20%; Adverse events listed by Medical Dictionary for Regulatory Activities (MedDRA) Preferred Term

Number of patients with NV1020 detected in saliva, skin, and/or mucosal surfaces; Analysis by polymerase chain reaction (PCR)

Number of patients with clinically significant hematology laboratory abnormalities by NV1020 dose cohort (Post baseline)

Number of patients with post-baseline clinically significant laboratory chemistry abnormalities by NV1020 dose cohort

Number of patients with post-baseline clinically significant laboratory coagulation abnormalities by NV1020 dose cohort

Maximum percentage changes in tumor diameter after administration of NV1020 followed by chemotherapy as measured by CT scan and Modified Response Evaluation Criteria in Solid Tumors (RECIST) assessment

Mean change from baseline in NV1020 neutralizing antibody titer by dose cohort

Progression assessed from CT and PET measurements and is determined as an increase of greater than or equal to 25% in the sum of the products of perpendicular diameters of all tumors, or the appearance of any new lesion.

Median change from baseline of Interferon (INF) gamma 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)

Median change from baseline of Interleukin-6 (IL-6) 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)

Median change from baseline of tumor necrosis factor (TNF-alpha) 8 hours post NV1020 infusion (Visits 1, 3, 5, 7)

MediGene

\*Serious adverse events exclude those which were deemed to be unrelated to NV1020

Escalating doses of NV1020: 3x10\^6, 1x10\^7, 3x10\^7, 1x10\^8

Age, Continuous

Sex: Female, Male

Caucasian

African American

Asian

Hispanic

Race/Ethnicity, Customized

Carcinoembryonic Antigen (CEA) Level at Screening

Prior Chemotherapy

KPS 100

KPS 90

KPS 80

The KPS was rated as follows:

100 - Normal, no complaints, no evidence of disease; 90 - Able to carry on normal activity; minor signs or symptoms of disease; 80 - Normal activity with effort; some signs or symptoms of disease

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma	NCT00669136	Hepatocellular ... Hepatoma Liver Cancer, A... Liver Cell Carc... Liver Cell Carc... Cancer of Liver Cancer of the L... Cancer, Hepatoc... Hepatic Cancer Hepatic Neoplas... Hepatocellular ... Liver Cancer Neoplasms, Hepa... Neoplasms, Live...	AFP + GM-CSF Pl...	18 Years - 80 Years	University of Pittsburgh
Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases	NCT02866344	Colorectal Neop... Neoplasm Metast... Hepatic Neoplas...	Microwave ablat... Hepatic resecti...	18 Years - 75 Years	Wake Forest University Health Sciences
Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma	NCT00669136	Hepatocellular ... Hepatoma Liver Cancer, A... Liver Cell Carc... Liver Cell Carc... Cancer of Liver Cancer of the L... Cancer, Hepatoc... Hepatic Cancer Hepatic Neoplas... Hepatocellular ... Liver Cancer Neoplasms, Hepa... Neoplasms, Live...	AFP + GM-CSF Pl...	18 Years - 80 Years	University of Pittsburgh
Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method	NCT02213692	Hepatic Neoplas...		18 Years - 80 Years	Fudan University
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma	NCT02939807	Carcinoma, Hepa...	ABC294640	18 Years -	Medical University of South Carolina
Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method	NCT02213692	Hepatic Neoplas...		18 Years - 80 Years	Fudan University
Identification of Hepatic Lesions	NCT00307866	Hepatic Neoplas...	Resovist (BAY86...	18 Years -	Bayer
Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)	NCT02246634	Colorectal Neop... Neoplasm Metast... Hepatic Neoplas...	Diffusion Weigh...	16 Years -	Imperial College London
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver	NCT00149396	Colorectal Canc... Liver Neoplasms	NV1020	18 Years -	MediGene
Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases	NCT02866344	Colorectal Neop... Neoplasm Metast... Hepatic Neoplas...	Microwave ablat... Hepatic resecti...	18 Years - 75 Years	Wake Forest University Health Sciences
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver	NCT00149396	Colorectal Canc... Liver Neoplasms	NV1020	18 Years -	MediGene

Spots Global Cancer Trial Database for hepatic neoplasms